Side Effect CJC-1295 + Ipamorelin HGH (Somatropin) Injection site reactions Common, mild Common, mild Water retention/edema Mild, transient Moderate to significant, dose-dependent Joint pain Rare Common at higher doses (carpal tunnel, arthralgia) Insulin resistance Not documented as significant Well-documented at supraphysiological doses Cortisol elevation Minimal (Ipamorelin is selective) Not directly caused by HGH Prolactin elevation Minimal (Ipamorelin advantage over GHRP-2/6) Not directly caused by HGH Organ enlargement risk Not documented (physiological GH levels) Documented at chronic supraphysiological doses Pituitary suppression Feedback loop preserved Natural GH production suppressed with prolonged use The side effect differential largely stems from the feedback loop distinction
Recent clinical data show semaglutide 2.4 mg achieved 14.9% mean weight loss at 68 weeks in STEP 1, while tirzepatidewhich targets dual GLP-1 and GIP receptorsproduces 2027% weight loss in comparable trials, yet individual outcomes vary significantly based on genetic predispositions in appetite and energy metabolism pathways
2013a;36:255965
Owners of dogs may report unilateral or bilateral lameness or paresis/paralysis, toe dragging, low tail or neck carriage, difficulties with rising, sitting or lying down, reluctance to jump or climb, urinary or faecal incontinence, and hyperesthesia or self-mutilation [11]
It is prudent for trainers to explain all potential risks to new clients, especially those who have never undertaken serious physical activity and may be significantly deconditioned
Medicare is legally barred from covering weight-loss drugs, but the Wegovy pill was also approved for lowering heart disease risk, which Medicare does cover
